Physician Assistant Program year 2023 Reported 2022–2023 Source: CMS Open Payments, 2026 publication

Kevin Jensen

Physician Assistant Reno, NV Physician Assistant

NPI 1205203585 CMS profile 11177683

975 Ryland St Ste 100, Reno, NV 89502

Open in the dashboard

General payments

$202

12 records reported · program years 2022–2023

Research payments

$0

Paid to them · None reported · program years 2022–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Kevin Jensen of Reno, NV is reported in the CMS Open Payments database as having received $202 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 39th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $55 3
2022 General $147 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Jensen
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kevin Jensen were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kevin Jensen Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $147 $155 $48–$522 $149
2023 $55 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2023
  1. AbbVie, Inc. $117 7 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $23 1 payment
  3. Lilly USA, LLC $18 1 payment
  4. Biohaven Pharmaceutical Holding Company Ltd. $16 1 payment
  5. Pfizer Inc. $16 1 payment
  6. Takeda Pharmaceuticals U.S.A., Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2023
  1. Food and Beverage $202 12 payments
Products named General payments · program years 2022–2023
  1. QULIPTA $79 5 payments
  2. Kerendia $23 1 payment
  3. SKYRIZI $23 1 payment
  4. JARDIANCE $18 1 payment
  5. EMGALITY $18 1 payment
  6. NURTEC ODT $16 1 payment
  7. PREVNAR 20 $16 1 payment
  8. PAXLOVID $16 1 payment
  9. UBRELVY $15 1 payment
  10. GATTEX $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

202

Median for Physician Assistant: 241

Drug cost

$1,689

Median for Physician Assistant: $4,110

Branded share of claims

27.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Albuterol Sulfate Hfa Albuterol Sulfate Brand 31 $608
Doxycycline Hyclate Generic 34 $268
Cefdinir Generic 27 $207
Methylprednisolone Generic 33 $185
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 24 $180
Fluticasone Propionate Generic 11 $93
Azithromycin Generic 16 $71
Cephalexin Generic 13 $56
Prednisone Generic 13 $21

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$23,754

Of which drugs: $57

Medicare patients

274

Average age 71

Services billed

518

181 women, 93 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 44%
Diabetes 25%
Depression 22%
Ischemic heart disease 21%
Chronic kidney disease 19%
COPD 18%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ketorolac tromethamine, per 15 mg J1885 Office 12 22 $9

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record